Circulating immune cell populations related to primary breast cancer, surgical removal, and radiotherapy revealed by flow cytometry analysis.
Biomarker
Breast cancer
CD117
FlowJo
Granulocytes
Monocytes
Radiotherapy
Unsupervised analysis
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
05 06 2021
05 06 2021
Historique:
received:
11
01
2021
accepted:
25
05
2021
entrez:
6
6
2021
pubmed:
7
6
2021
medline:
1
1
2022
Statut:
epublish
Résumé
Advanced breast cancer (BC) impact immune cells in the blood but whether such effects may reflect the presence of early BC and its therapeutic management remains elusive. To address this question, we used multiparametric flow cytometry to analyze circulating leukocytes in patients with early BC (n = 13) at the time of diagnosis, after surgery, and after adjuvant radiotherapy, compared to healthy individuals. Data were analyzed using a minimally supervised approach based on FlowSOM algorithm and validated manually. At the time of diagnosis, BC patients have an increased frequency of CD117 This study revealed changes in blood leukocytes associated with primary BC, surgical removal, and adjuvant radiotherapy. Specifically, it identified increased levels of CD117
Sections du résumé
BACKGROUND
Advanced breast cancer (BC) impact immune cells in the blood but whether such effects may reflect the presence of early BC and its therapeutic management remains elusive.
METHODS
To address this question, we used multiparametric flow cytometry to analyze circulating leukocytes in patients with early BC (n = 13) at the time of diagnosis, after surgery, and after adjuvant radiotherapy, compared to healthy individuals. Data were analyzed using a minimally supervised approach based on FlowSOM algorithm and validated manually.
RESULTS
At the time of diagnosis, BC patients have an increased frequency of CD117
CONCLUSIONS
This study revealed changes in blood leukocytes associated with primary BC, surgical removal, and adjuvant radiotherapy. Specifically, it identified increased levels of CD117
Identifiants
pubmed: 34090509
doi: 10.1186/s13058-021-01441-8
pii: 10.1186/s13058-021-01441-8
pmc: PMC8180078
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 31003A_159824
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 31003A_179248
Références
Mediators Inflamm. 2018 Jun 21;2018:5270657
pubmed: 30034290
Cell Death Dis. 2017 Sep 7;8(9):e3045
pubmed: 28880270
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
NPJ Breast Cancer. 2018 Apr 3;4:8
pubmed: 29644338
Clin Chim Acta. 2019 Mar;490:113-127
pubmed: 30597138
Int J Radiat Biol. 2019 Jul;95(7):936-939
pubmed: 31120369
Ann Oncol. 2012 Apr;23(4):1044-52
pubmed: 22373539
Cancer Res. 2016 Mar 1;76(5):1009-18
pubmed: 26833128
JAMA Surg. 2014 Mar;149(3):267-74
pubmed: 24429935
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Cancer Cells. 1991 Dec;3(12):480-7
pubmed: 1726456
Ann Surg Oncol. 2015 Nov;22(12):3836-45
pubmed: 25743325
Anticancer Res. 2005 Jul-Aug;25(4):3159-66
pubmed: 16080580
Clin Cancer Res. 2018 Nov 15;24(22):5735-5743
pubmed: 29784675
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8
pubmed: 12917485
Anticancer Res. 2019 Sep;39(9):4957-4963
pubmed: 31519601
Oncotarget. 2016 Mar 8;7(10):11137-50
pubmed: 26840567
Lancet Oncol. 2012 Apr;13(4):412-9
pubmed: 22373563
N Engl J Med. 2012 Nov 22;367(21):1998-2005
pubmed: 23171096
Cancer. 2013 Apr 1;119(7):1402-11
pubmed: 23359049
Immunotherapy. 2014;6(5):597-610
pubmed: 24896628
Acta Oncol. 2008;47(4):672-81
pubmed: 18465335
EMBO J. 2013 Mar 6;32(5):617-28
pubmed: 23395906
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
Cancer Res. 2016 Oct 15;76(20):5994-6005
pubmed: 27550452
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
Cancer Treat Rev. 2019 Feb;73:73-83
pubmed: 30682661
Cancer Treat Rev. 2015 Feb;41(2):187-96
pubmed: 25533736
Eur J Cancer. 2018 Mar;92:54-68
pubmed: 29413690
Lancet Oncol. 2016 Aug;17(8):1158-1170
pubmed: 27344114
Oncologist. 2007 Mar;12(3):253-70
pubmed: 17405890
Methods. 2008 Jan;44(1):31-8
pubmed: 18158130
Front Med (Lausanne). 2020 Feb 11;7:28
pubmed: 32118013
Cancer Lett. 2019 Jun 28;452:66-70
pubmed: 30902563
Int J Cancer. 2017 Oct 1;141(7):1295-1306
pubmed: 28542784
Haematologica. 1998 Jul;83(7):587-92
pubmed: 9718862
Sci Rep. 2018 Jun 21;8(1):9474
pubmed: 29930290
Semin Cancer Biol. 2012 Jun;22(3):174-86
pubmed: 22374376
Medicine (Baltimore). 2019 Jun;98(24):e16024
pubmed: 31192953
Autoimmunity. 2017 Mar;50(2):133-140
pubmed: 28263099
Biosensors (Basel). 2018 Jul 13;8(3):
pubmed: 30011807
Anticancer Res. 2009 May;29(5):1847-52
pubmed: 19443415
Clin Cancer Res. 2012 Aug 15;18(16):4365-74
pubmed: 22711708
Acta Med Austriaca. 1990;17(1):11-4
pubmed: 2353562
Histochem Cell Biol. 2008 Dec;130(6):1091-103
pubmed: 18987874
Oncoimmunology. 2015 Aug 17;5(2):e1075694
pubmed: 27057449
Biomedicines. 2018 Feb 11;6(1):
pubmed: 29439457
Clin Chim Acta. 2010 Dec 14;411(23-24):1869-74
pubmed: 20816948
Clin Cancer Res. 2018 Oct 1;24(19):4754-4762
pubmed: 29921729
Am J Med. 2013 Jun;126(6):472-9
pubmed: 23561631
N Engl J Med. 2002 Oct 17;347(16):1227-32
pubmed: 12393819
Am J Pathol. 2017 Oct;187(10):2152-2162
pubmed: 28733194
Cancers (Basel). 2019 Jan 31;11(2):
pubmed: 30709048